A TLR4-interacting peptide inhibits lipopolysaccharide-stimulated inflammatory responses, migration and invasion of colon cancer SW480 cells

OncoImmunology

Volumn 1, Issue 9, 2012, Pages 1495-1506

  Rakhesh, Madhusoodhanan ^a   Cate, Moriasi ^b   Vijay, Ramani ^a   Shrikant, Anant ^b   Shanjana, Awasthi ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Inflammation; NF B; Surfactant protein A; TLR4

Indexed keywords

CYCLOOXYGENASE 2; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; SPA4 PEPTIDE; SURFACTANT PROTEIN A; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELB; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER CELL; CELL INVASION; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BINDING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; MIGRATION INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84877067027     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22089     Document Type: Article

References (49)

1. Bosani M, Ardizzone S, Porro GB. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics 2009; 3:77-97; PMID:19707398.
2. Ho RJ, Chien JY. Drug delivery trends in clinical trials and translational medicine: growth in biologic molecule development and impact on rheumatoid arthritis, Crohn's disease, and colitis. J Pharm Sci 2012; 101:2668-74; PMID:22573521; http://dx.doi.org/10.1002/jps.23154.
3. Ngo B, Farrell CP, Barr M, Wolov K, Bailey R, Mullin JM, et al. Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety. Curr Mol Pharmacol 2010; 3:145-52; PMID:20799925.
4. Fukata M, Shang L, Santaolalla R, Sotolongo J, Pastorini C, España C, et al. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis 2011; 17:1464- 73; PMID:21674704; http://dx.doi.org/10.1002/ibd.21527.
5. Rahman FZ, Smith AM, Hayee B, Marks DJ, Bloom SL, Segal AW. Delayed resolution of acute inflammation in ulcerative colitis is associated with elevated cytokine release downstream of TLR4. PLoS One 2010; 5:e9891; PMID:20360984; http://dx.doi.org/10.1371/journal.pone.0009891.
6. Török HP, Glas J, Tonenchi L, Mussack T, Folwaczny C. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 2004; 112:85-91; PMID:15207785; http://dx.doi.org/10.1016/j.clim.2004.03.002.
7. Tang XY, Zhu YQ, Wei B, Wang H. Expression and functional research of TLR4 in human colon carcinoma. Am J Med Sci 2010; 339:319-26; PMID:20228668.
8. He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007; 44:2850- 9; PMID:17328955; http://dx.doi.org/10.1016/j.molimm.2007.01.022.
9. Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 2009; 28:4353-63; PMID:19826413; http://dx.doi.org/10.1038/onc.2009.289.
10. Killeen SD, Wang JH, Andrews EJ, Redmond HP. Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NFkappaBdependent activation of the urokinase plasminogen activator system. Br J Cancer 2009; 100:1589-602; PMID:19436306; http://dx.doi.org/10.1038/sj.bjc.6604942.
11. Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, Rousseau S, et al. LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrinmediated cell adhesion and liver metastasis. Cancer Res 2011; 71:1989-98; PMID:21363926; http://dx.doi.org/10.1158/0008-5472.CAN-10-2833.
12. Wang JH, Manning BJ, Wu QD, Blankson S, Bouchier-Hayes D, Redmond HP. Endotoxin/lipopolysaccharide activates NFkappa B and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism. J Immunol 2003; 170:795-804; PMID:12517943.
13. Awasthi S, Brown K, King C, Awasthi V, Bondugula R. A toll-like receptor-4-interacting surfactant protein- A-derived peptide suppresses tumor necrosis factor-a release from mouse JAWS II dendritic cells. J Pharmacol Exp Ther 2011; 336:672-81; PMID:21159752; http://dx.doi.org/10.1124/jpet.110.173765.
14. Rubio S, Lacaze-Masmonteil T, Chailley-Heu B, Kahn A, Bourbon JR, Ducroc R. Pulmonary surfactant protein A (SP-A) is expressed by epithelial cells of small and large intestine. J Biol Chem 1995; 270:12162- 9; PMID:7744866; http://dx.doi.org/10.1074/jbc.270.20.12162.
15. Awasthi S, Coalson JJ, Crouch E, Yang F, King RJ. Surfactant proteins A and D in premature baboons with chronic lung injury (Bronchopulmonary dysplasia). Evidence for an inhibition of secretion. Am J Respir Crit Care Med 1999; 160:942-9; PMID:10471623.
16. Awasthi S, Coalson JJ, Yoder BA, Crouch E, King RJ. Deficiencies in lung surfactant proteins A and D are associated with lung infection in very premature neonatal baboons. Am J Respir Crit Care Med 2001; 163:389-97; PMID:11179112.
17. Awasthi S, Magee DM, Coalson JJ. Coccidioides posadasii infection alters the expression of pulmonary surfactant proteins (SP)-A and SP-D. Respir Res 2004; 5:28; PMID:15588319; http://dx.doi.org/10.1186/1465-9921-5-28.
18. Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, Greene KE, et al. By binding SIRPalpha or calreticulin/ CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 2003; 115:13-23; PMID:14531999; http://dx.doi.org/10.1016/S0092-8674(03)00758-X.
19. Awasthi S, Madhusoodhanan R, Wolf R. Surfactant protein-A and toll-like receptor-4 modulate immune functions of preterm baboon lung dendritic cell precursor cells. Cell Immunol 2011; 268:87-96; PMID:21439559; http://dx.doi.org/10.1016/j.cellimm.2011.02.009.
20. Yamada C, Sano H, Shimizu T, Mitsuzawa H, Nishitani C, Himi T, et al. Surfactant protein A directly interacts with TLR4 and MD-2 and regulates inflammatory cellular response. Importance of supratrimeric oligomerization. J Biol Chem 2006; 281:21771- 80; PMID:16754682; http://dx.doi.org/10.1074/jbc.M513041200.
21. Carpenter S, O'Neill LA. Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins. Biochem J 2009; 422:1-10; PMID:19627256; http://dx.doi.org/10.1042/BJ20090616.
22. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009; 458:1191-5; PMID:19252480; http://dx.doi.org/10.1038/nature07830.
23. Medzhitov R, Janeway CA Jr. Innate immune recognition and control of adaptive immune responses. Semin Immunol 1998; 10:351-3; PMID:9799709; http://dx.doi.org/10.1006/smim.1998.0136.
24. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998; 2:253-8; PMID:9734363; http://dx.doi.org/10.1016/S1097-2765(00)80136-7.
25. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, et al. A novel heterodimeric cysteine protease is required for interleukin- 1 beta processing in monocytes. Nature 1992; 356:768-74; PMID:1574116; http://dx.doi.org/10.1038/356768a0.
26. Symons JA, Eastgate JA, Duff GW. A soluble binding protein specific for interleukin 1 beta is produced by activated mononuclear cells. Cytokine 1990; 2:190- 8; PMID:2151765; http://dx.doi.org/10.1016/1043-4666(90)90015-L.
27. Eastgate JA, Symons JA, Duff GW. Identification of an interleukin-1 beta binding protein in human plasma. FEBS Lett 1990; 260:213-6; PMID:2137098; http://dx.doi.org/10.1016/0014-5793(90)80106-S.
28. May LT, Viguet H, Kenney JS, Ida N, Allison AC, Sehgal PB. High levels of "complexed" interleukin-6 in human blood. J Biol Chem 1992; 267:19698-704; PMID:1527089.
29. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006; 66:3859-68; PMID:16585214; http://dx.doi.org/10.1158/0008-5472.CAN-05-3948.
30. Kutikhin AG. Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Hum Immunol 2011; 72:1095-116; PMID:21872627; http://dx.doi.org/10.1016/j.humimm.2011.07.307.
31. Slattery ML, Herrick JS, Bondurant KL, Wolff RK. Toll-like receptor genes and their association with colon and rectal cancer development and prognosis. Int J Cancer 2012; 130:2974-80; PMID:21792899; http://dx.doi.org/10.1002/ijc.26314.
32. Petricevic B, Vrbanec D, Jakic-Razumovic J, Brcic I, Rabic D, Badovinac T, et al. Expression of Toll-like receptor 4 and beta 1 integrin in breast cancer. Med Oncol 2012; 29:486-94; PMID:21400218; http://dx.doi.org/10.1007/s12032-011-9885-0.
33. Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, et al. High expression of Tolllike receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 2010; 102:908-15; PMID:20145615; http://dx.doi.org/10.1038/sj.bjc.6605558.
34. Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, et al. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res 2010; 29:92; PMID:20618976; http://dx.doi.org/10.1186/1756-9966-29-92.
35. Lan LS, Ping YJ, Na WL, Miao J, Cheng QQ, Ni MZ, et al. Down-regulation of Toll-like receptor 4 gene expression by short interfering RNA attenuates bone cancer pain in a rat model. Mol Pain 2010; 6:2; PMID:20089147; http://dx.doi.org/10.1186/1744-8069-6-2.
36. Earl TM, Nicoud IB, Pierce JM, Wright JP, Majoras NE, Rubin JE, et al. Silencing of TLR4 decreases liver tumor burden in a murine model of colorectal metastasis and hepatic steatosis. Ann Surg Oncol 2009; 16:1043-50; PMID:19165543; http://dx.doi.org/10.1245/s10434-009-0325-8.
37. van Rozendaal BA, van Golde LM, Haagsman HP. Localization and functions of SP-A and SP-D at mucosal surfaces. Pediatr Pathol Mol Med 2001; 20:319-39; PMID:11486736; http://dx.doi.org/10.1080/152279501750412243.
38. Awasthi S. Surfactant protein (SP)-A and SP-D as antimicrobial and immunotherapeutic agents. Recent Pat Antiinfect Drug Discov 2010; 5:115-23; PMID:20230362; http://dx.doi.org/10.2174/157489110791233559.
39. Moulakakis C, Adam S, Seitzer U, Schromm AB, Leitges M, Stamme C. Surfactant protein A activation of atypical protein kinase C zeta in IkappaB-alphadependent anti-inflammatory immune regulation. J Immunol 2007; 179:4480-91; PMID:17878344.
40. Wu Y, Adam S, Hamann L, Heine H, Ulmer AJ, Buwitt-Beckmann U, et al. Accumulation of inhibitory kappaB-alpha as a mechanism contributing to the anti-inflammatory effects of surfactant protein- A. Am J Respir Cell Mol Biol 2004; 31:587-94; PMID:15308505; http://dx.doi.org/10.1165/rcmb.2004-0003OC.
41. Alcorn JF, Wright JR. Surfactant protein A inhibits alveolar macrophage cytokine production by CD14- independent pathway. Am J Physiol Lung Cell Mol Physiol 2004; 286:L129-36; PMID:12959932; http://dx.doi.org/10.1152/ajplung.00427.2002.
42. Lee CH, Wu CL, Shiau AL. Toll-like receptor 4 signaling promotes tumor growth. J Immunother 2010; 33:73-82; PMID:19952954; http://dx.doi.org/10.1097/CJI.0b013e3181b7a0a4.
43. Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009; 69:3105-13; PMID:19318560; http://dx.doi.org/10.1158/0008-5472.CAN-08-3838.
44. Gatti G, Quintar AA, Andreani V, Nicola JP, Maldonado CA, Masini-Repiso AM, et al. Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. Prostate 2009; 69:1387-97; PMID:19496069; http://dx.doi.org/10.1002/pros.20984.
45. Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009; 86:557-66; PMID:19451397; http://dx.doi.org/10.1189/jlb.1008647.
46. Ghose AK, Crippen GM. Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships. I. Partition coefficients as a measure of hydrophobicity. J Comput Chem 1986; 7:565-77; http://dx.doi.org/10.1002/jcc.540070419.
47. Giacometti A, Cirioni O, Ghiselli R, Mocchegiani F, D'Amato G, Circo R, et al. Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock. Am J Respir Crit Care Med 2004; 169:187- 94; PMID:14563656; http://dx.doi.org/10.1164/rccm.200307-971OC.
48. Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M, et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 1998; 188:2163-73; PMID:9841929; http://dx.doi.org/10.1084/jem.188.11.2163.
49. Kim HR, Wheeler MA, Wilson CM, Iida J, Eng D, Simpson MA, et al. Hyaluronan facilitates invasion of colon carcinoma cells in vitro via interaction with CD44. Cancer Res 2004; 64:4569-76; PMID:15231668; http://dx.doi.org/10.1158/0008-5472.CAN-04-0202.